NPS Hopes For A Happy New Year With Catalysts And Growth Ahead
This article was originally published in The Pink Sheet Daily
Executive Summary
The new year is set to be a pivotal one for the rare disease specialist, which expects to launch its short bowel disease drug teduglutide in Europe and have a second product, Natpara, approved in the U.S.
You may also be interested in...
NPS Executes On Ultra-Orphan Gattex Launch With FDA Approval In Hand
NPS Pharmaceuticals will price the short bowel syndrome treatment at $295,000 per year – in line with the cost of other drugs in the ultra-orphan spectrum and higher than some industry observers expected – but said the addressable patient population is lower than it previously estimated.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.